Option chain shows key data for Avicanna's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Avicanna.

Avicanna (OTC:AVCNF) Stock, Option Chain

Avicanna Inc is an innovative, commercial-stage, and international biopharmaceutical company focused on the development, advancement, and commercialization of evidence-based cannabinoid-based products for the global consumer, as well as medical and pharmaceutical market segments. In global cannabinoid advancements, it conducts most of its research in Canada at its research and development headquarters in JLABS in Toronto, located in the MaRS Discovery District. The company actively collaborates with Canadian academic and medical institutions. Avicanna has established a scientific platform including research and development and clinical development which led to the commercialization of more than twenty products across four main market segments.

avcn-pr-q3-rsults-2024-linkedin-x-q3-2024nov14

Cannabis

Earnings

News

AVCNF

Avicanna Reduces Net Loss And Improves Gross Profit, Focusing On International Markets

Screen Shot 2024-10-24 at 13.36.47

Latin America

Regulations

Exclusives

Interview

CLVR

FLGC

OWPC

PCLOF

TSX:AVCN

Colombia&#39;s cannabis decree allows dry flower sales, but ex-official claims it won&#39;t just protect small producers—most companies may qualify.

Cannabis Flower Sales In Colombia And The Small Producer Protection Myth: Ex-Official Says Most Companies Qualify

pexels-kindelmedia-7667731

Government

Health Care

Politics

Global

CBD could be deemed toxic for reproduction, which would then lead to its prohibition in cosmetic products across Europe.

CBD&#39;s Toxicity Concerns: Could Europe Ban Cannabidiol In Cosmetics?

Avicanna Inc

FORTY

Formula Sys (1985) Q3 EPS $1.51 Up From $1.00 YoY, Sales $699.9M Up From $654.8M YoY

Yiren Digital (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/YRD#NYSE">YRD</a>) reported quarterly earnings of $0.57 per share. This is a 32.51 percent decrease over earnings of $0.85 per share from the same period last year. The company reported $210.77 million in sales this quarter. This is a 17.32 percent increase over sales of $179.66 million the same period last year.

Yiren Digital Q3 2024 EPS $0.57 Down From $0.85 YoY, Sales $210.77M Up From $179.66M YoY

The solution provides organizations worldwide with the opportunity to benefit from Memorial Sloan Kettering Cancer Center (MSK)'s best-in-class comprehensive genomic profiling (CGP) application on the SOPHiA DDM Platform with high accuracy and efficiency.

General

SOPH

SOPHiA GENETICS Announced The Global Launch Of MSK-impact Powered With Sophia DDM From The Association For Molecular Pathology Annual Meeting

Baozun (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BZUN#NASDAQ">BZUN</a>) reported quarterly losses of $(1.12) per share. This is a 12.5 percent increase over losses of $(1.28) per share from the same period last year. The company reported quarterly sales of $2.06 billion which beat the analyst consensus estimate of $1.91 billion by 7.98 percent. This is a 12.80 percent increase over sales of $1.82 billion the same period last year.

BZUN

Baozun Q3 2024 GAAP EPS RMB(1.12) Up From RMB(1.28) YoY, Sales RMB2.06B Beat RMB1.91B Estimate

Yunji (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/YJ#NASDAQ">YJ</a>) reported quarterly losses of $(0.86) per share. This is a 10650 percent decrease over losses of $(0.01) per share from the same period last year. The company reported $12.35 million in sales this quarter. This is a 37.92 percent decrease over sales of $19.90 million the same period last year.

Yunji Q3 EPS $(0.86) Down From $(0.01) YoY, Sales $12.35M Down From $19.90M YoY

Subsea 7 (OTC:<a class="ticker" href="https://www.benzinga.com/stock/SUBCY#OTC">SUBCY</a>) reported quarterly earnings of $0.31 per share. This is a 181.82 percent increase over earnings of $0.11 per share from the same period last year. The company reported $1.83 billion in sales this quarter. This is a 16.22 percent increase over sales of $1.58 billion the same period last year.

SUBCY

Subsea 7 Q3 EPS $0.31 Up From $0.11 YoY, Sales $1.83B Up From $1.58B YoY

<ul>
<li>In this first cohort, eight participants received a dose of 0.25 mg LP-310, with promising initial results. No product-related serious adverse events were reported. Pharmacokinetic data demonstrated that whole blood tacrolimus levels in all patients were either undetectable or minimal, highlighting LP-310's potential to deliver localized therapeutic effects while minimizing systemic exposure. Additionally, all patients tolerated LP-310 without significant adverse reactions.</li>
<li>Following a successful internal safety evaluation of the first dose cohort, the trial has received approval to advance to the next stage of the trial, which will evaluate a higher dose of 0.5 mg of LP-310.</li>
</ul>

Biotech

LIPO

Lipella Pharmaceuticals Has Completed Dosing For The First Cohort In Its Phase 2A Trial Of LP-310, A Liposomal-tacrolimus Oral Rinse Being Developed For Oral Lichen Planus, Topline Data Is Expected By Year-end And Complete The Trial By Mid-2025

KE Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BEKE#NYSE">BEKE</a>) reported quarterly earnings of $1.53 per share which missed the analyst consensus estimate of $1.57 by 2.55 percent. The company reported quarterly sales of $22.58 billion which missed the analyst consensus estimate of $23.46 billion by 3.74 percent. This is a 825.16 percent increase over sales of $2.44 billion the same period last year.

BEKE

KE Holdings Q3 2024 Adj EPADS RMB1.53 Misses RMB1.57 Estimate, Sales RMB22.58B Miss RMB23.46B Estimate

TD Cowen analyst Andrew Charles reiterates Jack In The Box (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JACK#NASDAQ">JACK</a>) with a Hold and maintains $50 price target.

Price Target

Reiteration

Analyst Ratings

JACK

TD Cowen Reiterates Hold on Jack In The Box, Maintains $50 Price Target

Needham analyst Bernie McTernan maintains Wix.com (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WIX#NASDAQ">WIX</a>) with a Buy and raises the price target from $200 to $235.

Needham Maintains Buy on Wix.com, Raises Price Target to $235

Delta Air Lines Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DAL#NASDAQ">DAL</a>) CEO Ed Bastian has suggested that President-elect Donald Trump&#8216;s administration could provide a &#8220;breath of fresh air&#8221; for the airline industry, criticizing what he perceives as government &#8220;overreach&#8221; during President Joe Biden&#8216;s era.
What Happened: Speaking ahead of the company&#8217;s investor day, Bastian signaled potential regulatory changes that could significantly impact the aviation sector, <a href="https://apnews.com/article/delta-airlines-trump-biden-regulation-c4393d5f763d95c8286d4069563032dc#">reported</a> the Associated Press on Thursday.
The airline executive&#8217;s comments reflect a broader sentiment among industry leaders who anticipate a more business-friendly regulatory environment. 
Southwest Airlines Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LUV#NYSE">LUV</a>) CEO Robert Jordan similarly expressed hope for a Department of Transportation that might be &#8220;less aggressive&#8221; in rule-making, highlighting growing frustration with current consumer protection regulations.
See Also: <a href="https://www.benzinga.com/24/11/42102366/bitcoin-taps-95k-ethereum-dogecoin-flat-as-trumps-crypto-policy-takes-shape-top-analyst-describes-btcs-path-to-135k">Bitcoin Hits $95K For The First Time Ever, Ethereum, Dogecoin Flat As Trump&#8217;s Crypto Policy Takes Shape</a>
Delta&#8217;s financial performance provides context for these expectations. The airline reported a robust $2.6 billion profit in the first nine months of 2024, with projected fourth-quarter adjusted profit between $1.60 and $1.85 per share. The company expects 2025 revenue growth in mid-single digits, positioning itself strongly amid potential regulatory shifts.
Why It Matters: Wall Street appears cautiously optimistic about <a href="https://www.benzinga.com/general/travel/24/11/42014787/delta-united-alaska-air-are-top-analyst-picks-in-airline-sector">the airline sector&#8217;s future</a>. Goldman Sachs has resumed coverage of major airlines, providing Delta with a &#8220;Buy&#8221; rating and an $83 price target. Analysts expect continued supply constraints through 2025, with a focus on airlines&#8217; ability to adapt to changing market conditions.
The potential appointment of Sean Duffy as Transportation Secretary could herald broader changes across the transportation sector. Industry <a href="https://www.benzinga.com/24/11/42076876/what-could-trumps-new-dot-pick-mean-for-evs-airlines-railroads">observers speculate about the potential streamlining of regulations</a>, enhanced infrastructure focus, and possible modifications to electric vehicle and autonomous driving policies.
Price Action: Delta Air Lines closed at $63.64 on Wednesday, down 1.71% for the day. In pre-market trading, the stock was down 0.5% at the time of writing. Year to date, the stock has surged by 57.33%, according to <a href="https://pro.benzinga.com/dashboard">data from Benzinga Pro</a>.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/personal-finance/24/11/42044634/653125">Dave Ramsey Recalls The Day American Express Called His Wife, Asking Why Stay &#8216;With A Man That Won&#8217;t Pay His Bills.&#8217; Here&#8217;s What He Did Next</a></li>
</ul>
Image Via Shutterstock
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Equities

Markets

Delta Chief Says Trump Could Be A 'Breath Of Fresh Air' For Aviation Industry

William Blair analyst Dylan Carden downgrades Ulta Beauty (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ULTA#NASDAQ">ULTA</a>) from Outperform to Market Perform.

Downgrades

ULTA

William Blair Downgrades Ulta Beauty to Market Perform

Target Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TGT#NYSE">TGT</a>) and Walmart Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WMT#NYSE">WMT</a>) released their September quarter results just a day apart. Target&#8217;s management highlighted that its customers were most active during sales and promotional events, while Walmart&#8217;s leadership attributed 75% of its market share growth to households earning six-figure incomes.
Target&#8217;s executive vice president and chief commercial officer company Rick Gomez said that their consumers &#8220;know there are deals to be found, they&#8217;re willing to wait for sales and willing to search across multiple retailers.&#8221; While the latter&#8217;s chief executive officer, Doug McMillon attributed <a href="https://www.benzinga.com/news/earnings/earnings-beats/24/11/42085839/us-retail-giant-walmarts-growth-is-fueled-by-75-of-its-customers-earning-in-six-figures-ceo-doug-mcmillon-explains">75% of their market share gains</a> to "households earning more than $100,000."
Also read: <a href="https://www.benzinga.com/news/earnings/earnings-beats/24/11/42085839/us-retail-giant-walmarts-growth-is-fueled-by-75-of-its-customers-earning-in-six-figures-ceo-doug-mcmillon-explains">Walmart Market Share Surges As Six-Figure Income Households Drive 75% Of Growth In Q3: &#8216;People Come To Us To Shop As A Primary Destination&#8217;</a>
What Happened: Gomez highlighted that Target&#8217;s consumers were looking for promotions with an example. &#8220;Our Target Circle week this quarter was one of our biggest yet. However, we saw a more pronounced sales dip both the week before and the week after the event, showing just how planful consumers are in seeking out promotions when they shop.&#8221;
&#8220;Similarly, we saw consumers lean into everyday essential stock-up promotions throughout the quarter to further stretch their monthly budgets. We saw a strong reaction to promotions throughout the quarter,&#8221; he added.
On the flip side, John David Rainey the chief financial officer of Walmart re-affirmed his CEO&#8217;s view and said, &#8220;we're seeing higher engagement across income cohorts with upper-income households continuing to account for the majority of our share gains.&#8221;
Why It Matters: Shares of Target Corporation plunged by 21.41% to close at $121.72 apiece, on Wednesday, as compared to a 0.16% advance in the NYSE Composite Index. <a href="https://www.benzinga.com/news/earnings/24/11/42085436/target-q3-earnings-supply-chain-chaos-hits-bottomline-slashes-annual-profit-outlook-stock-tanks">Target&#8217;s third-quarter</a> adjusted earnings per share of $1.85, missed the street view of $2.30. Quarterly total revenue of $25.67 billion (+1.1% year over year) missed the analyst consensus estimate of $25.90 billion.
Brian Cornell, chair and chief executive officer of Target said, "We encountered some unique challenges and cost pressures that impacted our bottom-line performance.&#8221; The third-quarter gross margin rate decreased by 0.2 percentage points to 27.2%.
Also read: <a href="https://www.benzinga.com/news/earnings/24/11/42085436/target-q3-earnings-supply-chain-chaos-hits-bottomline-slashes-annual-profit-outlook-stock-tanks">Target Q3 Earnings: Supply Chain Chaos Hits Bottomline, Slashes Annual Profit Outlook, Stock Tanks</a>
On Tuesday, <a href="https://www.benzinga.com/pressreleases/24/11/b42058916/walmart-reports-strong-revenue-growth-of-5-5-with-operating-income-growing-faster-at-8-2">Walmart&#8217;s third-quarter results</a> beat estimates and the fiscal 2025 guidance was raised. Its shares rose 3% on Tuesday, while it was further up by 0.67% to $87.18 apiece as per Wednesday&#8217;s close.
Walmart&#8217;s ales were at $169.59 billion, up 5.5% year over year or 6.2% (at constant currency), beating the consensus of $167.72 billion. The gross margin rate was up 21 bps to 24.2% aided by improvement in the Walmart U.S. Operating income was up by $0.5 billion or 8.2% year over year at $6.7 billion.
Price Action: On a year-to-date basis, Walmart has surged by 64.19%, while Target is down by 14.94%, according to <a href="http://pro.benzinga.com">Benzinga Pro</a> data. The NYSE Composite Index was up 17.26% in the same period. In Thursday&#8217;s premarket, TGT shares were up 0.5%. 
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="272" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/21041932/Walmart-vs-TGT-1024x272.png" alt="" class="wp-image-658433" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/21041932/Walmart-vs-TGT-1024x272.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/21041932/Walmart-vs-TGT-300x80.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/21041932/Walmart-vs-TGT-768x204.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/21041932/Walmart-vs-TGT-1536x408.png 1536w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/21041932/Walmart-vs-TGT.png 1741w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read next: <a href="https://www.benzinga.com/24/11/42103600/us-dollar-may-test-10860-level-as-geopolitical-tensions-cautious-fed-rhetoric-and-solid-us-economic-data-may-push-the-greenback-higher-says-expert">Dollar Upside On The Cards Amid Geopolitical Tensions, Cautious Fed And Solid US Economic Data, Says Expert</a>
Image via Flickr/ Mike Mozart

Earnings Beats

Earnings Misses

Target Says Shoppers Wait For 'Deals' A Day After Rival Walmart Credits Market Gains To Wealthy Households: TGT Edges Up Marginally In Thursday Premarket

RBC Capital analyst Brian Abrahams upgrades Sage Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAGE#NASDAQ">SAGE</a>) from Underperform to Sector Perform and maintains the price target from $4 to $4.

Upgrades

SAGE

RBC Capital Upgrades Sage Therapeutics to Sector Perform, Maintains Price Target to $4

Piper Sandler analyst Brent Bracelin reiterates Snowflake (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNOW#NYSE">SNOW</a>) with a Overweight and raises the price target from $165 to $185.

SNOW

Piper Sandler Reiterates Overweight on Snowflake, Raises Price Target to $185

Tesla Inc.&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) new vehicle registrations in the EU are continuing to drop, <a href="https://www.benzinga.com/tech/24/11/41892379/tesla-offers-a-year-of-supercharging-for-free-in-europe-as-it-chases-record-q4-deliveries-to-outpace-a-slowdown">threatening the company&#8217;s global EV delivery target</a> for the year.
What Happened: Tesla had 11,088 vehicle registrations in the European Union in October, marking a drop of 21% from the corresponding period last year, according to data from the European Automobile Manufacturers' Association (ACEA). 
This is despite battery electric vehicle registrations rising 2.4% in the EU last month to 124,907 units on the back of growing popularity in Denmark and the Netherlands. 
Tesla had 192,661 new vehicle registrations in the EU from January through the end of October, marking a drop of over 11% year-on-year. 
For the full year 2023, Tesla delivered 1,808,581 vehicles around the globe. To mark a growth over last year, the company has to deliver at least 514,926 vehicles in the three months through the end of December. Tesla has never managed to deliver over 500,000 EVs in a quarter to date, making this an ambitious target.
Why It Matters: In the third quarter, Tesla reported deliveries of 462,890 vehicles, up 6.4% year-over-year and up 4.3% quarter-over-quarter.
Deliveries fell 8.5% year-on-year in the first quarter and by 4.8% in the second quarter.
According to Tesla researcher Troy Teslike, the low sales in Europe are likely to impact Tesla&#8217;s aim to prevent a drop in yearly deliveries. 
&#8220;Tesla is trying to reach 514,925 deliveries this quarter to avoid a drop in yearly totals compared to the 1,808,581 units delivered last year. However, even if they sell out all their inventory in the US, it's still going to be tough to hit that number because sales in Europe are down too,&#8221; <a href="https://www.benzinga.com/tech/24/11/41894615/tesla-q4-deliveries-expected-to-set-new-records-but-not-enough-to-avoid-yearly-sales-decline-says-researcher">Teslike said</a> in a post on X earlier this week.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Tesla is trying to reach 514,925 deliveries this quarter to avoid a drop in yearly totals compared to the 1,808,581 units delivered last year. However, even if they sell out all their inventory in the US, it's still going to be tough to hit that number because sales in Europe are… <a href="https://t.co/fflyf175xp">https://t.co/fflyf175xp</a>
&mdash; Troy Teslike (@TroyTeslike) <a href="https://twitter.com/TroyTeslike/status/1858430634315943990?ref_src=twsrc%5Etfw">November 18, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Price Action: Tesla stock fell 1.2% on Wednesday to close at $342.03, and declined over 1% in premarket trading on Thursday. Year-to-date, the stock is up 37.7%, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro data</a>.
Check out more of Benzinga's Future Of Mobility coverage by <a href="https://www.benzinga.com/topic/mobility" target="_blank" rel="noreferrer noopener">following this link.</a>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/42056899/jim-cramer-thinks-trumps-plans-for-robotaxis-are-fanciful-but-he-is-still-bullish-on-tesla-stock-the-musk-premium-will-work-its-magic-in-other-ways" target="_blank" rel="noreferrer noopener">Jim Cramer Thinks Trump's Plans For Robotaxis Are ‘Fanciful,' But He Is Still Bullish On Tesla Stock: ‘The Musk Premium Will Work Its Magic In Other Ways'</a></li>
</ul>
Photo courtesy: Shutterstock

Tech

TSLA

Tesla Registrations Drop By Over 20% In October In EU, Possibly Hindering Its 2024 Global EV Delivery Target

Macquarie analyst Austin Yun upgrades Piedmont Lithium (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLL#NASDAQ">PLL</a>) from Underperform to Neutral and announces $13.5 price target.

Macquarie Upgrades Piedmont Lithium to Neutral, Announces $13.5 Price Target

<ul>
<li>Rolling forward its mid-term guidance with strong 2024 performance as the base year, Novartis now expects to grow sales at +5% CAGR 2024-2029.&nbsp;</li>
<li>The company remains on track to deliver core operating income margin1 of 40%+ by 2027, benefiting from continued strong sales growth and productivity improvements.</li>
<li>"Novartis has completed its transformation into a pure-play innovative medicines company, with deep expertise and capabilities across our core therapeutic areas and technology platforms. Our focus has allowed us to sharpen our commercial execution and increase our peak sales estimates for Cosentyx, Kisqali, Kesimpta, Pluvicto and Leqvio, and we have more than 15 submission-enabling readouts in the coming years to further bolster our growth profile," said Vas Narasimhan, CEO of Novartis. "Longer term, we've identified more than 30 assets in the pipeline with significant potential to rejuvenate our portfolio and support mid-single-digit growth post 2029. Taken together, we remain confident in our focused strategy and ability to deliver sustainable value creation for shareholders."</li>
</ul>

Large Cap

Guidance

Novartis Upgrades Its Mid-term Guidance. Previous Guidance For +5% Sales CAGR 2023-2028 Was Upgraded To +6%, Driven By Strong Momentum Of In-market Growth Drivers And Upcoming Launches, Most Of Which Have Expected US Exclusivity In 2030's Or Beyond

HSBC analyst Carlos Gomez-Lopez initiates coverage on Marex Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRX#NASDAQ">MRX</a>) with a Buy rating and announces Price Target of $33.

Initiation

HSBC Initiates Coverage On Marex Group with Buy Rating, Announces Price Target of $33

The Offering is expected to close on or about November 25, 2024, subject to customary closing conditions.
The Company estimates that the net proceeds from the sale of the Notes, after deducting initial purchaser discounts but before deducting the other estimated expenses of the offering, will be approximately US$124.2 million (or approximately US$143.5 million if the initial purchasers exercise their option to purchase additional Notes in full). The Company intends to use the net proceeds from the Offering (including any net proceeds from the sale of any additional Notes that may be sold should the initial purchasers exercise their option to purchase additional Notes) for the construction of copper-gold mining projects outside of China, for the exploration and development of other projects and for working capital.

Silvercorp Metals Prices $130M 4.75% Convertible Senior Notes Due 2029

Avicanna (TSE:AVCN) has released an update. Avicanna Inc. has reported a significant revenue increase of 85% in Q2 2024, reaching $6.1 million, whi...

Avicanna Reports Strong Growth and Medical Trials Success

Avicanna (TSE:AVCN) has released an update. Avicanna Inc., a biopharmaceutical company specializing in cannabinoid-based products, has announced si...

Avicanna Soars with Strong Q2 Growth and R&D Success

Avicanna reports Q2 results

Avicanna (TSE:AVCN) has released an update. Avicanna Inc., a biopharmaceutical company, has been granted a US patent for its innovative topical can...

Avicanna Secures US Patent for Pain-Relief Topical Technology

Avicanna (TSE:AVCN) has released an update. Avicanna Inc., a biopharmaceutical company, has successfully completed a non-brokered private placement...

Avicanna Completes Private Placement Fundraising

Avicanna (TSE:AVCN) has released an update. Avicanna Inc., an international biopharmaceutical company, has successfully paid off its $1,445,000 deb...

Avicanna Clears Debt, Advances Cannabinoid Solutions

Avicanna (TSE:AVCN) has released an update. Avicanna Inc., a biopharmaceutical company, has launched a significant study on medical cannabis with 1...

Avicanna Launches Major Cannabis Effects Study

Avicanna (TSE:AVCN) has released an update. Avicanna Inc., a global biopharmaceutical company, has successfully closed a non-brokered private place...

Avicanna Secures $800K in Private Placement

Avicanna (TSE:AVCN) has released an update. Avicanna Inc. reported a significant 75% increase in revenue for the first nine months of 2024, reachin...

Comments

Avicanna

Avicanna (AVCNF) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga